Fox Run Management L.L.C. Sells 41,121 Shares of Amicus Therapeutics, Inc. $FOLD

Key Points

• Fox Run Management L.L.C. significantly reduced its holdings in Amicus Therapeutics (NASDAQ:FOLD) by 65.7%, selling 41,121 shares and leaving it with 21,449 shares valued at approximately $175,000.
• Despite the reduction from Fox Run, other hedge funds like PNC Financial Services and GAMMA Investing have increased their stakes, indicating mixed activity among institutional investors in Amicus Therapeutics.
• Recent analyst reports have shown a generally positive outlook, with upgrades from firms like Morgan Stanley and UBS, and a target price averaging around $16.22 for the stock.

Fox Run Management L.L.C. cut its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 65.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,449 shares of the biopharmaceutical company's stock after selling 41,121 shares during the period. Fox Run Management L.L.C.'s holdings in Amicus Therapeutics were worth $175,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. raised its stake in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 425,419 shares of the biopharmaceutical company's stock worth $4,007,000 after acquiring an additional 7,204 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Amicus Therapeutics by 539.1% during the fourth quarter. Russell Investments Group Ltd. now owns 53,282 shares of the biopharmaceutical company's stock worth $502,000 after buying an additional 44,945 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $132,000. Marshall Wace LLP increased its stake in Amicus Therapeutics by 254.2% in the fourth quarter. Marshall Wace LLP now owns 72,968 shares of the biopharmaceutical company's stock valued at $687,000 after purchasing an additional 52,368 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of Amicus Therapeutics by 7.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 80,076 shares of the biopharmaceutical company's stock valued at $753,000 after buying an additional 5,522 shares during the period.

Amicus Therapeutics Trading Up 0.5%

NASDAQ:FOLD traded up $0.04 during mid-day trading on Tuesday, hitting $7.52. 2,919,436 shares of the company's stock were exchanged, compared to its average volume of 4,428,290. The company has a 50 day simple moving average of $6.42 and a 200-day simple moving average of $7.15. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The firm has a market capitalization of $2.32 billion, a P/E ratio of -62.66 and a beta of 0.53.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on FOLD. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. The Goldman Sachs Group cut their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Finally, Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Amicus Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.